Polarean Imaging PLC (LON:POLX) has received an order for its drug-device technology from University of Texas MD Anderson Cancer Center, a world-leading research and teaching hospital.
The 9820 Xenon Polariser will be used to assess lung function after chemotherapy and radiation therapies, providing guidance for improved radiation treatment planning, the company said.
In a statement, Polarean chief executive Richard Hullihen commented: "We are excited to begin our relationship with MD Anderson Cancer Center who have pioneered such a breadth of oncology applications for medical imaging for this patient population, and welcome them to the group of our users researching the use of hyperpolarised 129 Xe in pulmonary function."
The company has developed a drug-device combination which uses hyperpolarised 129-Xenon gas alongside magnetic resonance imaging (MRI).
By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.